Zydus to acquire Assertio in $166m deal

Zydus Lifesciences is set to acquire all outstanding Assertio common shares in a $166.4m deal, via its subsidiary Zydus Worldwide DMCC. The deal is expected to close in the second quarter of 2026, pending customary closing conditions. Upon completion of the tender, Zydus will acquire any remaining shares through a second-step merger at the same price. Credit: Piotr Swat / Shutterstock.com. Zydus Lifesciences (Zydus) is set to acquire all outstanding Assertio common shares in a deal valued at around $166.4m, through its subsidiary Zydus Worldwide DMCC. The offer was approved by Assertio’s Board of Directors, following a revised merger agreement…

Source: Pharmaceutical Technology